Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom
Authors' conclusion
Our findings reflect some discrepancy between the available evidence and prescribing behaviour for SGLT2 inhibitors.
Study context
- Population
- New metformin users initiating SGLT2i or DPP-4i between January 2013 and October 2019, UK Clinical Practice Research Datalink (CPRD) primary care data linked to hospital and death records
- Participants
- 2,550 vs 8,195
- Exposure
- SGLT2i vs DPP-4i initiation
- SGLT2 inhibitorsn = 2,550
- DPP-4 inhibitorsn = 8,195reference
- Outcome
- Treatment discontinuation (first 90-day gap after estimated treatment end date)
Methodological detailscomparative, extended Cox models with time-dependent predictors, exposure-predictor interaction terms
- Comparative
- Extended Cox models with time-dependent predictors
- Exposure-predictor interaction terms
Main finding
As reported in the abstract
end of follow-up
| Group | Value | HR of discontinuation after fracture |
|---|---|---|
| SGLT2i | 69% | 4.13 (95% CI 2.12-8.06) |
| DPP-4i | 74% | 0.93 (95% CI 0.79-1.11) |
Value
SGLT2i69%
DPP-4i74%
HR of discontinuation after fracture
SGLT2i4.13 (95% CI 2.12-8.06)
DPP-4i0.93 (95% CI 0.79-1.11)
Observational data: associations, not effects.
Original publication
Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom. Diabetes Obes Metab. Published 10 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →